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ABSTRACT
We report the first dry-reagent, disposable, dipstick
test for molecular screening of seven chromosomal
translocations associated with acute and chronic
leukemia. The dipstick assay offers about 10 times
higher detectability than agarose gel electropho-
resis and, contrary to electrophoresis, allows con-
firmation of the sequence of the polymerase chain
reaction (PCR) product by hybridization within a few
minutes without the need of instrumentation.
Biotinylated amplified DNA is hybridized with a dA-
tailed probe and applied to the strip, which contains
oligo(dT)-conjugated gold nanoparticles in dry form.
Upon immersion of the strip in the appropriate
buffer, the solution migrates and the hybrids are
captured by immobilized streptavidin at the test
zone generating a characteristic red line. The excess
nanoparticles are captured by oligo(dA) strands
immobilized at the control zone of the strip
producing a second red line. We studied the:
t(9;22)(q34;q11), t(15;17)(q22;q21), t(11;17)(q23;q21),
t(5;17)(q32;q21), t(11;17)(q13;q21), t(8,21)(q22;q22)
and inv(16)(p13;q22) that generate the BCR-ABL,
PML-RARa, PLZF-RARa, NPM-RARa, NuMA-RARa,
AML1-ETO and CBFb-MYH11 fusion genes,
respectively. A single K562 cell was detectable
amidst 10
6 normal leukocytes. A dipstick test was
developed for actin, as a reference gene. The
dipstick assay with appropriate probes can be
used for identification of the fusion transcripts
involved in the translocation.
INTRODUCTION
Chromosomal translocations have a primary role in the
pathogenesis of leukemia because they aﬀect speciﬁc genes
encoding transcription factors or other cell-cycle regula-
tors. The structural and functional characterization of
these rearrangements has provided valuable insight into
the mechanisms of malignant transformation of the
hematopoietic cells (1–3). Moreover, the fusion genes
that are formed as a result of the translocations constitute
important tumor markers whose detection and/or quanti-
ﬁcation assist in the diagnosis, prognosis, monitoring the
response to treatment and detection of minimal residual
disease (4–6). The chimeric proteins that are encoded by
the fusion genes in the leukemic cells could in principle
serve as tumor markers but there is a lack of suitable
antibodies for the development of immunoassays (7).
Conventional cytogenetics and ﬂuorescence in situ
hybridization (FISH) are used widely for the detection
of chromosomal rearrangements albeit their sensitivity is
limited to 1–5% of leukemic cells in the total cell
population (1,4,5). To date the highest detectability is
achieved by methods that are based on the exponential
ampliﬁcation of translocation-speciﬁc nucleic acid
sequences, e.g. via the polymerase chain reaction (PCR).
Molecular studies of chromosomal rearrangements have
shown that the breakpoints in various patients are spread
over a large segment of genomic DNA, which is diﬃcult
to amplify by PCR on a routine basis. The resulting fusion
mRNA transcripts, however, are the same in most
patients and consequently RNA is preferred as a starting
template for the molecular assays of chromosomal
translocations (1–6). PCR primers are designed to
hybridize at opposite sides of the junction region so that
exponential ampliﬁcation occurs only when the fusion
sequence is present in the sample.
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detection of PCR products entails separation by agarose
gel electrophoresis followed by ethidium bromide staining.
Hybridization assays that are performed in microtitration
wells have been proposed for the post-PCR detection of
ampliﬁed products because they are easily automatable
(8,9). However, they require specialized instrumentation
and multiple pipetting, incubation and washing steps in
order to capture the ampliﬁed sequence, hybridize with a
speciﬁc probe, remove the excess of probe, add the
appropriate substrate and read the generated signal.
Alternatively, ﬂow cytometry can be used for post-PCR
detection of ampliﬁcation products that are ﬂuorescently
labeled or have been subjected to an oligonucleotide
ligation reaction and are captured on polystyrene beads
(10,11). Flow cytometry is suitable for the development of
multiplex assays but requires expensive instrumentation.
On the other hand, real-time PCR allows continuous
monitoring of the ampliﬁed fragments during PCR by a
homogeneous ﬂuorometric hybridization assay and is used
widely for quantiﬁcation of the fusion transcripts. Real-
time PCR, however, requires highly specialized, expensive
equipment along with costly reagents (1,4,5).
In this work, we report the ﬁrst dry-reagent, disposable,
dipstick test for the molecular screening of chromosomal
translocations. The test allows visual detection and
conﬁrmation of PCR-ampliﬁed leukemia-speciﬁc tran-
scripts by hybridization within minutes. The test is simple
and does not require special instrumentation. A total of
seven well-deﬁned chromosomal rearrangements were
selected. The Philadelphia translocation,
t(9;22)(q34;q11), which is present in 495% of patients
with chronic myeloid leukemia (CML), involves the
movement of most of the ABL (Abelson murine leukemia)
protooncogene from chromosome 9 to the BCR (break-
point cluster region) gene on chromosome 22, thus
resulting in the BCR-ABL fusion gene (12). The
t(15;17)(q22;q21) translocation, which is the diagnostic
hallmark of acute promyelocytic leukemia (APL), joins
the PML (promyelocytic leukemia) gene on chromosome
15 with the retinoic acid receptor alpha gene (RARa) on
17q to produce the PML-RARa fusion gene (1,3,13).
Three other chromosomal translocations, associated with
acute myeloid leukemia (AML), disrupt the RARa gene,
namely, the t(11;17)(q23;q21) that involves the PLZF
(promyelocytic leukaemia zinc ﬁnger) gene, the
t(5;17)(q32;q21) implicating the NPM (nucleophosmin)
gene and the t(11;17)(q13;q21) that involves the gene
encoding the nuclear mitotic apparatus protein (NuMA).
The generated fusion transcripts are PLZF-RARa, NPM-
RARa and NuMA-RARa, respectively (1,3,13). Also two
other common translocations with a signiﬁcant prognostic
value for AML were detected: The t(8,21)(q22;q22),
that fuses the acute myeloid leukaemia 1 (AML1) gene
with the ETO (eight twenty one) gene (generating the
AML1-ETO fusion gene) and the inv(16)(p13;q22) that
joins the CBFb (core binding factor beta) gene on 16q22
and the MYH11 (myosin smooth muscle heavy chain)
gene on chromosome 16p13 to produce the CBFb-
MYH11 fusion (14,15).
MATERIALS AND METHODS
Instrumentation
PCR ampliﬁcation was performed in a thermal cycler
from MJ Research (Waltham, MA). A digital camera,
Kodak DC 120, and the Gel Analyzer software for
DNA documentation were purchased from Kodak
(New York, NY).
Materials
Agarose, deoxynucleoside triphosphates (dNTPs) and
DNA molecular weight markers ( 174 DNA, HaeIII
digest) were obtained by HT Biotechnology (Cambridge,
UK). Ethidium Bromide was purchased from Research
Organics (Cleveland, OH). TRIzol Reagent and
SuperScript II reverse transcriptase were obtained from
Invitrogen (CarlsBad, CA). Taq DNA polymerase was
purchased from Hytest (Turku, Finland), Promega
(Madison, WI) and Finzymes (Espoo, Finland).
Ribonuclease inhibitor (RNasin) was from Promega
(Madison, WI). Terminal deoxynucleotidyl transferase
(TdT) was purchased from MBI Fermentas (Vilnius,
Lithuania). All common reagents were from Sigma
(St. Louis, MO). The dry-reagent DNA strip was
manufactured as described earlier (16).
Plasmids pSG5-PLZF-RARa, pSG5-NPM-RARa and
pSG5-NuMA-RARa containing the PLZF-RARa, the
NPM-RARa and the NuMA-RARa complete fusion
c-DNAs at the EcoRI site of the vector pSG5 were
kindly provided by Dr Jonathan Licht (Division of
Hematology-Oncology, Mount Sinai School of
Medicine, NY) (17,18). Samples for BCR-ABL, PML-
RARa, AML1-ETO and CBFb-MYH11 were collected at
the Division of Hematology, University Hospital, Rio,
Patras, Greece. The NB4 cell line (ACC 207) carrying the
PML-RARa translocation was obtained from DSMZ
(Braunschweig, Germany).
The primers and probes used in this study were
synthesized by Invitrogen. Primer sequences for BCR-
ABL (8,9), PML-RARa, NPM-RARa (19), PLZF-RARa
(20) NuMA-RARa (21), CBFb-MYH11 (22) and AML1-
ETO (22) are listed in Table 1. Actin was ampliﬁed by
using 50-Biotin-ACAATGAGCTGCGTGTGGCT-30 and
50-TCTCCTTAATGTCACGCACGA-30 as upstream and
downstream primer, respectively. The oligonucleotide
probes used for the detection of ampliﬁed DNA were as
follows: BCR-ABL,5 0-GCTGAAGGGCTTTTGAACTC
TGCTTA-30 (b3-a2) (8,9), 50-AGTGGCTGAGTGGACG
ATGACATT-30 (b3) and 50-GCTGAAGGGCTTCTTCC
TTATTGATG-30 (b2-a2) (8,9); PML-RARa,5 0-ATCTT
GATGACCTTCCTGGGGACT-30; PLZF-RARa,
50-GTACGTCTTCATCCCACTGTGCAGC-30, NPM-
RARa,5 0-GCCTTCGTAATTCATTGCCTCTGCT-30,
NuMA-RARa,5 0-GCTGAGTTGCCATAATCGGGA
GA-30, AML1-ETO,5 0-TCT CAGTACGATTTCGA
GGTTCTC-30, CBFb-MYH11,5 0-CAGCTCATGG
ACCTC-30 and Actin,5 0-TCTCAAACATGATCTGG
GTCATCT-30 (23).
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Bone marrow or peripheral blood samples from 22
patients with a diagnosis of Ph
1 CML, based on cytology,
histology, cytogenetic and molecular analysis, were used
for the detection of BCR-ABL transcripts. The clinical
information, including disease phase, type of therapy,
hematological, cytogenetic and molecular remission status
are presented in Table 2. Complete hematologic response
was deﬁned according to conventional criteria: (1) bone
marrow with 55% blasts (2) peripheral blood leukocyte
count 510000 per ml without peripheral blasts, promy-
elocytes or myelocytes (3) disappearance of all signs and
symptoms related to CML (4) normalization for at least 4
weeks. Cytogenetic response was deﬁned by prevalence of
Ph
1 metaphases: 0%, complete; 1–35%, partial; 35–65%,
minor; 65–95%, minimal; greater that 95%, none. For
patients 2, 3, 5 and 8, two samples were obtained at
diﬀerent time points in the course of the disease. The study
also included two patients with essential thrombocythemia
which were used as negative controls. Two patient samples
carrying the b2-a2 BCR-ABL transcript variant were
kindly provided by Dr D. Mavrogianni, (Laiko Hospital,
University of Athens Medical School, Athens, Greece).
For detection of AML-related fusion transcripts, PML-
RARa, AML1-ETO and CBFB-MYH11 bone marrow or
peripheral blood samples were obtained from 4 AML
patients at the time of disease diagnosis: one AML-M3
(APL) patient carrying the t(15;17) translocation, two
patients with AML-M2 carrying the translocation t(8;21)
and one AML-M4 patient with the inv(16) chromosomal
rearrangement. The speciﬁc chromosomal aberrations
were detected by routine karyotyping and PCR analysis.
The samples were obtained from Hematology Division,
Department of Internal Medicine, University of Patras
Medical School, Patras, Greece.
RNA extraction
The total mononuclear cells from patient samples were
isolated by Ficoll density gradient centrifugation using the
Biocoll separating solution from Biochrom (Berlin,
Germany). The total RNA was isolated from about 10
6
cells by using the TRIzol reagent.
Reverse transcription (RT)
Reverse transcription reactions were carried out in a total
volume of 20ml containing 50 mM Tris-HCl, pH 8.3, 75
mM KCl, 3 mM MgCl2, 10 mM dithiothreitol, 0.5mM
each of the dNTPs, 0.5mM downstream external primer,
40 U RNasin, 200 U reverse transcriptase and 5ml (1–5mg)
total RNA. The reactions mixtures were incubated for 1h
at 428C and then held for 15min at 708C.
Polymerase chain reaction (PCR)
Two rounds of PCR (nested PCR) were performed for
each chromosomal translocation. All ampliﬁcations were
carried out in a total volume of 50ml in the presence of 67
mM Tris-HCl, pH 8.8, 16.6 mM (NH4)2SO4, and 0.1ml/l
Tween-20. The upstream primers used for the second
round of PCR (PCR II) were biotinylated at the 50 end.
The other components of the reaction mixtures along with
cycling conditions are given in the next paragraphs:
BCR-ABL. PCR I was carried out by using 0.5mM each
of the primers A1 and A2 (upstream and downstream
primer, respectively), 1.5 mM MgCl2,4 0 mM each of the
dNTPs, 1.25 U thermostable DNA polymerase and 1mlo f
the reverse transcription (RT) mixture. The program of
thermal cycling included: 5min at 958C followed by 20
cycles of 958C for 30s, 658C for 30s and 728Cf o r1 m i n .
At the end of the cycling, the mixture was held at 728Cf o r
10min. A 1-ml aliquot was used for PCR II (35 cycles),
which was performed exactly as PCR I using oligos A3 and
A4 as upstream and downstream primers, respectively.
PML-RARa. PCR I was carried out by using 0.5mM each
of the primers B1 and B2, 1.5 mM MgCl2, 200mM each of
the dNTPs and 2.5 U DNA polymerase. The RT mixture
was treated for 20min, at 378C, with 2 U of RNase H and
2ml of a 3-fold dilution was used for ampliﬁcation. The
cycling steps were: 3min at 958C followed by 35 cycles of
948C for 45s, 658C for 45s and 728C for 1min, and a ﬁnal
Table 1. Sequences of the primers used in nested PCR (PCR I and
PCR II)
Fusion genes PCR I
Primers (50 !30)
PCR II
primers* (50 !30)
BCR-ABL A1 TTTCAGAAGCT
TCTCCCTGAC
A3 GGAGCTGCA
GATGCTGACCAAC
A2 CAGTGC
AACGAAAA
GGTTGGG
GTC
A4 TCAGACCCT
GAGGCTCAAAGTC
PML-RARa B1 AGCTGATCCGC
GAGCGCGTG
B3 CAACGACAGC
CCAGAAGAGGAAGT
B2 TGGATG
CTGCGGCG
GAAGAAGC
CCTTGCAG
B4 ATAGTGGTAG
CCTGAGGACTTGTC
PLZF-RARa C1 TCCAGAGGGA
GCTGTTCAGC
C2 TCGAGCTTCCTGA
TAACGAG
R1 TCTTCTG
GATGCTGC
GGCGG
R2 GGCGCTGACCCC
ATAGTGGT
NPM-RARa D1 GGAAGATTCGAT
GGACATGG
D2 TCGGTTGTGAACA
AAGGCC
R1 TCTTCTG
GATGCTGC
GGCGG
R2 GGCGCTGACCCC
ATAGTGGT
NuMA-RARa E1 AGACCTGGGCAA
ATTCCAGG
E2 TTCTACAGCACG
CGGTCTGC
R1 TCTTCTG
GATGCTGC
GGCGG
R2 GGCGCTGACCCC
ATAGTGGT
AML1-ETO F1 CTACCGCAGCCA
TGAAGAACC
F3 ATGACCTCAGGTT
TGTCGGTCG
F2 AGAGGA
AGGCCCAT
TGCTGAA
F4 TGAACTGGTTCTT
GGAGCTCCT
CBFb-MYH11 G1 GCAGGCAAGGTA
TATTTGAGGG
G3 GGGCTGTCTGG
AGTTTGATG
G2 TCCTCTT
CTCCTCATT
CTGCTC
G4 CTTGAGCGCCTGC
ATGTT
 All the upstream primers used for PCR II are biotinylated at the
50end.
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product was added to the PCR II mixture, which was
performed with primers B3 and B4 and 1 mM MgCl2. The
cycling parameters for PCR II were: 5min at 958C
followed by 35 cycles of 948C for 30s, 658C for 30s and
728C for 50s and a ﬁnal step at 728C for 10min.
AML1-ETO. Primers F1 and F2 (0.5mM of each) were
used for PCR I along with 1.5 mM MgCl2, 200mM each of
the dNTPs, 2.5 U DNA polymerase and 1ml of the RT
mixture. A 1-ml aliquot of the product was used for PCR
II, which was performed with primers F3 and F4. The
PCR conditions included 30s at 958C followed by 35
cycles for PCR I (30 cycles for PCR II) at 948C for 30s,
658C for 1min and 728C for 1min. At the end of the
cycling, the mixture was held at 728C for 10min.
CBFb-MYH11. Primers G1 and G2 (0.5mM of each) were
used for PCR I along with 2.5 mM MgCl2,5 0mM each of
the dNTPs, 1.25 U DNA polymerase and 1ml of the RT
mixture. A 2-ml aliquot of the product was used for PCR
II, which was performed with primers G3 and G4. The
thermal cycling conditions for both rounds of PCR were:
1min at 958C followed by 35 cycles of 948C for 30s, 658C
for 1min and 728C for 1min. At the end of the cycling, the
mixture was held at 728C for 10min.
PLZF-RARa and NPM-RARa. Oligos C1 and D1
(0.2mM of each) were used as upstream primers for
PCR I of PLZF-RARa and NPM-RARa, respectively,
whereas the oligo R1 was used as a downstream primer for
both ampliﬁcations. The reaction mixture contained 1.5
mM MgCl2, 200mM each of the dNTPs and 2.5 U DNA
polymerase. A 1-ml volume of the product was transferred
into the PCR II mixture. Oligos C2 and D2 served as
upstream primers of PLZF-RARa and NPM-RARa,
respectively, and R2 was the downstream primer. The
cycling program for both PCR rounds comprised 5min at
958C followed by 35 cycles of 948C for 30s, 558C for 1min
and 728C for 1min. A ﬁnal extension step for 10min at
728C was performed.
NuMA-RARa. PCR I was performed by using 0.5mM
each of the primers E1 and R1, 1.5 mM MgCl2,5 0 mM
each of the dNTPs and 1.25 U DNA polymerase. PCR II
was carried out with primers E2 and R2 and 1mlo fa
10-fold dilution of the PCR I product. The PCR
conditions were as follows. Five minutes at 948C followed
by 20 cycles (for PCR I) or 25 cycles (for PCR II) of 948C
for 30s, 658C for 30s (688C for 30s for PCR II) and 728C
for 1min. At the end of the cycling, the mixture was held
at 728C for 10min.
Actin. The PCR mixture contained 10 mM Tris-HCl, pH
8.8, 50 mM KCl and 1 ml/l Triton X-100, 2.5 mM MgCl2,
50mM each of the dNTPs, 0.5mM each of the primers,
1.25 U DNA polymerase and 2ml of a 10-fold dilution of
the RT mixture. The PCR conditions were as follows. Five
minutes at 958C followed by 35 cycles of 958C for 30s,
608C for 30s and 728C for 1min. At the end of the cycling,
the mixture was held at 728C for 10min.
Negative controls (containing water instead of target)
were included in each series of reverse transcription and
ampliﬁcation reactions to conﬁrm the absence of contam-
ination. The PCR products were ﬁrst detected by 2%
agarose gel electrophoresis and ethidium bromide staining.
Table 2. Characteristics of chronic myelogenous leukemia patients
Sample No Patient Age
 /Sex Time point of analysis Disease phase at
diagnosis/hematologic
response to treatment
Cytogenetic analysis PCR
1 1 68/M At diagnosis Chronic phase CML 100% Ph
þ metaphases þ
2 2 60/F During therapy with HU No response none CR-100% Ph
þ metaphases þ
3 2 62/F During therapy with imatinib No response NA þ
4 3 71/M During therapy with imatinib CHR Minimal CR-86% Ph
þ metaphases þ
5 3 73/M During therapy with imatinib CHR Comlete CR-0% Ph
þ metaphases þ
6 4 51/M No therapy CHR Partial CR-15% Phþ metaphases þ
7 5 64/F During therapy with imatinib CHR Comlete CR -0% Ph
þ metaphases  
8 5 62/F During therapy with IFN/Ara-C No response Minimal CR-85% Ph
þ metaphases þ
9 6 31/F During therapy with imatinib CHR NA þ
10 7 24/M During therapy with imatinib CHR Minor CR-55% Ph
þ metaphases þ
11 8 63/F During therapy with HU CHR NA þ
12 8 64/F During therapy with imatinib CHR NA þ
13 9 69/F During therapy with imatinib CHR Partial CR -15% Ph
þ metaphases þ
14 10 69/M During therapy with IFN Blast crisis NA þ
15 11 22/M After allogeneic BMT CHR Complete CR-0% Ph
þ metaphases þ
16 12 68/F No therapy CHR NA þ
17 13 51/F At diagnosis Chronic phase CML 100% Ph
þ metaphases þ
18 14 49/F At diagnosis Chronic phase CML 100% Ph
þ metaphases þ
19 15 74/M During therapy with HU No response NA þ
20 16 48/F During therapy with imatinib/IFN No response None CR-100% Ph
þ metaphases þ
21 17 63/F During therapy with IFN CHR NA þ
22 18 31/F During therapy with imatinib CHR Complete CR-0% Ph
þ metaphases þ
 Age refers to the time of obtaining the sample.
CHR: complete hematologic response, CR: cytogenetic response, HU: hydroxyurea, IFN: interferon-a, BMT: bone marrow transplatation, NA:
not available.
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Oligonucleotide probes speciﬁc for the junction corre-
sponding to each chromosomal translocation were tailed
with dATP using terminal deoxynucleotidyl transferase
(TdT). The tailing reactions were carried out in a ﬁnal
volume of 20ml containing 0.2M potassium cacodylate, 25
mM Tris (pH 7.2), 0.1 ml/l Triton X-100, 1 mM CoCl2,2
mM dATP, 400 pmol probe and 30 U of TdT. The
mixture was incubated at 378C for 1h and the reaction was
stopped by adding 2ml of 0.5M EDTA, pH 8.0.
Methylmaleimide was also added at the end of the
incubation time at a ﬁnal concentration of 2.5 mM.
Dipstick test forrapid visual detection of translocation-
specific amplified sequences
The dry-reagent strip (4 mm 70mm) consisted of an
immersion pad, a conjugation pad, a laminated memb-
rane and an absorbent pad assembled on a plastic
adhesive backing that provides rigidity. The four parts
were positioned in such a way that their ends overlapped
in order to ensure continuous ﬂow (by capillary action)
of the developing solution from the wicking pad up to the
absorbent pad. Gold nanoparticles (40nm diameter)
functionalized with poly(dT) strands, as described pre-
viously (16), were placed on the conjugate pad and
allowed to dry at room temperature. Streptavidin (27 pmol)
was immobilized by physical adsorption on the test zone of
the strip. Similarly, poly(dA) strands (1.2 pmol) were
immobilized on the control zone of the strip.
Following PCR ampliﬁcation, the biotinylated products
were mixed with 1pmol of the tailed oligonucleotide probe
and the volume was brought to 5ml with 67 mM Tris-HCl,
pH 8.8, 16.6 mM (NH4)2SO4 and 0.1 ml/l Tween-20. The
mixture was then denatured by adding 5ml of 0.4M
NaOH and incubated for 10min at room temperature.
The mixture was neutralized by the addition of 5mlo f
0.4M HCl and 5ml of 0.4M Tris-HCl, pH 7.5 and allowed
to hybridize for 7min at 378C. A 10-ml aliquot of the
solution was applied to the conjugate pad of the strip and
the latter was immersed into the appropriate developing
solution (40 g/l glycerol and 10 g/l SDS in phosphate-
buﬀered saline, pH 7.4). The formation of a red line in the
test zone of the strip signiﬁes the presence of a
translocation-speciﬁc ampliﬁed sequence in the sample.
A red line is always formed at the control zone of the strip
to conﬁrm the proper functioning of the test. Thus, a
result is positive when a red line is observed both in the
test zone and control zone, whereas in the absence of the
translocation, a red line is formed only in the control zone.
RESULTS AND DISCUSSION
Assayprinciple
The proposed method for molecular diagnosis of several
leukemia-related chromosomal translocations involves
reverse transcription, ampliﬁcation of the related junction
sequences by nested PCR (PCR I and PCR II) and
detection of the products by the dry-reagent dipstick
assay. PCR II products were biotinylated at the one end
by using an upstream primer labeled with biotin at the 50
end. The sizes of PCR II products were 200bp for BCR-
ABL b3-a2 transcript, 124bp for BCR-ABL b2-a2, 366bp
for PML-RARa, 267bp for PLZF-RARa, 423bp for
NPM-RARa, 315bp for NuMA-RARa, 260bp for
AML1-ETO and 271bp for CBFb-MYH11. The integrity
of extracted total RNA was conﬁrmed by RT-PCR (one
round) of actin mRNA, as a reference gene. The PCR
product of actin was 372 bp. A similar dry-reagent
dipstick assay was also developed for the detection of
actin ampliﬁcation product.
A schematic illustration of the dry-reagent dipstick test
is presented in Figure 1. The assay entails rapid
hybridization of the ampliﬁed fragments (target DNA),
in solution, with a dATP-tailed oligonucleotide probe,
application to the sample loading area on the
conjugate pad of the strip and immersion of the strip
Au
SA
Flow
Au
Sample (S)
B Au
CP
AP
M
C
IP
CP 4800x CP 100x
M 1500x M 33150 x
Figure 1. Left panel: Illustration of the principle of the dry-reagent disposable dipstick test for visual detection of chromosomal translocations. Right
panel: Scanning electron microscopy (SEM) images of the conjugate pad and the membrane of the strip. IP¼immersion pad; CP¼conjugation pad;
M¼membrane; AP¼absorbent pad; TZ¼test zone; CZ¼control zone; SA¼streptavidin; B¼biotin.
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The developing solution migrates to the opposite end of
the strip, by capillary forces, and causes rehydration of the
poly(dT)-functionalized gold nanoparticles (Au NP),
which are then connected to the probe via hybridization
of the poly(dT) strands with the poly(dA) tail of the probe.
As the solution passes through the test zone of the strip,
the hybrids are captured by immobilized streptavidin, thus
resulting in accumulation of Au NP which is detected
visually as a characteristic red line. The red color of the
Au NP is due to the plasmon resonance peak at 520nm
(24,25). The excess of poly(dT)-Au NP are captured by
immobilized poly(dA) strands at the control zone of the
strip, giving a second red line. In the absence of the
translocation, no red line is observed at the test zone.
A red line, however, is always formed at the control
zone to conﬁrm the proper functioning of the strip.
Consequently, a sample is positive for a certain transloca-
tion when a red line is observed both in the test and the
control zone. Scanning electron microscope (SEM) images
of the conjugate pad (consisting of glass ﬁbers) and the
polyethersulfone membrane of the strip containing the Au
NP are also presented in Figure 1.
The assay conﬁguration described above is a hetero-
geneous hybridization assay. The conventional way of
performing this type of hybridization assays involves
pipetting the sample on a streptavidin-coated solid phase
(e.g. microtitration wells), incubation, washing the solid
phase, addition of an appropriately labeled detection
probe, incubation, washing out the excess of labeled probe
and measuring the signal of the probe that is bound to the
solid phase. The strip-based assay oﬀers the following
signiﬁcant advantages: (a) It eliminates the multiple
pipetting and washing steps required for addition of
reagents and separation of the bound from the free labeled
(not hybridized) probe. Indeed, the continuous migration
of the developing solution along the strip allows rapid
reagent mixing, hybridization, binding to the solid
phase and eﬃcient removal of the excess of labeled
probe. (b) It provides an appropriate amount of Au NP-
labeled probe in dry form as an integral part of the strip,
thus eliminating the need for reconstitution of reagents
and dilution of the stock solution.
The detectability of the dipstick assay was assessed, for
each chromosomal translocation and for actin, by
preparing solutions containing various concentrations of
ampliﬁed DNA. The DNA concentration of each stock
solution was determined by agarose gel electrophoresis
and ethidium bromide staining followed by densitometric
analysis of the picture of the gel taken by a digital camera.
The  174 DNA markers were used as standards for the
quantiﬁcation. Afterwards, serial dilutions of the stock
were prepared (using 67 mM Tris-HCl, pH 8.8, 16.6 mM
(NH4)2SO4, and 0.1 ml/l Tween-20) and 10-ml aliquots
containing from 0 to 400 fmol target DNA were assayed
by the strip.
BCR-ABL translocation
The results for the BCR-ABL translocation are presented
in Figure 2. As low as 0.4 fmol of the ampliﬁed target
0 1  2 3 4 5 6 7 8 9 10  11  12
Total RNA from K562 cells (10−1pg –5x106 pg)
M N 1 2 3 4 5  M  6  7  8  9  10 11  12 
200bp 
0  0.4 1.6 6.4 25 100 400 0  0.4 1.6 6.4 25 100 400
M N 0.4 1.6 6.4 25  100 400 M 0 0.4 1.6 6.4 25 100 400
200bp
BCR-ABL amplified DNA (fmol) Actin amplified DNA (fmol)
372bp 
Figure 2. Upper left panel: Dry-reagent dipstick test for the detection of ampliﬁed DNA from BCR-ABL translocation. Upper right panel: Dry-
reagent dipstick test for the detection of ampliﬁed DNA from the reference gene, actin. Lower panel: Dry-reagent dipstick test for the detection of
total RNA from a Philadelphia chromosome positive cell line (K562 cells). The amounts of RNA, in pg, are as follows. 1:0.1; 2:0.5; 3:2.56; 4:12.8;
5:64; 6:320; 7:1.6 10
3; 8:8 10
3; 9:4 10
4; 10:2 10
5; 11:10
6; 12:5 10
6. The results obtained by agarose (2%) gel electrophoresis and ethidium
bromide staining are also presented for direct comparison. M¼DNA markers; N¼negative, i.e. addition of water instead of RNA in the RT mixture.
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the intensity of the red line in the test zone of the strip
increases as the amount of target DNA increases up to
100fmol (10 nM). At 400fmol target DNA (40nM),
the intensity becomes lower than the line intensity at
100fmol DNA. This is attributed to the competition
between reannealing of the two strands of target DNA
and probe/target hybridization. A constant amount of
1 pmol poly(dA)-tailed probe was used throughout this
work. The amount of probe was estimated experimentally
and is determined by the number of poly(dT) strands on
the surface of Au NP that are available for hybridization.
The strip-based assay was compared directly (same
amount of product) with agarose gel electrophoresis and
ethidium bromide staining. The electropherograms are
also presented in Figure 2. The lowest amount of ampliﬁed
DNA detectable by electrophoresis was 6.4fmol. Thus,
the strip test for BCR-ABL ampliﬁed DNA provides
16 times better detectability than electrophoresis.
Data pertaining to the detection of the ampliﬁcation
product from the reference gene, actin, are also presented
in Figure 2. As low as 1.6fmol of actin ampliﬁed DNA
can be easily detected by visual observation, whereas
25fmol DNA are detectable by electrophoresis.
The sensitivity of the proposed assay for BCR-ABL,
including reverse transcription, nested PCR and strip-
based detection, was estimated as follows. Total RNA was
isolated from Philadelphia chromosome-positive cells
(K562 cells) and diluted (serial 5-fold dilutions) using
1g/l of yeast tRNA as a diluent. Solutions containing
0.1pg to 5 10
6 pg total RNA from Ph
1-positive cells
were subjected to RT, nested PCR and dipstick assay as
described in the experimental section. The results are
presented in Figure 2. For comparison, 5ml of the
ampliﬁed products were electrophoresed in 2% agarose
gel and detected by staining with ethidium bromide
(Figure 2). We were able to detect as low as 0.1 pg of
total RNA by the strip assay whereas 2.56 pg RNA were
barely detectable by electrophoresis. Again, the intensity
of the red line in the test zone is related to the RNA level
of the sample.
The overall sensitivity and speciﬁcity of the proposed
method were also assessed by spiking experiments, in
which normal leukocytes were spiked with K562 cells
covering a range of 0–10
6 K562 cells in a total population
of 10
6 cells. Following RNA isolation and reverse
transcription, a 2-ml aliquot was used for PCR I and 1ml
of the product was used for PCR II. Subsequently, a 5-ml
aliquot of ampliﬁed DNA was hybridized with the speciﬁc
probe (b3-a2) in a total volume of 20 and 10ml of the
mixture was applied to the strip. The results are presented
in Figure 3A. It is observed that the proposed method is
able to detect a single K562 cell amidst 10
6 normal
leukocytes, whereas 100 K562 cells were barely detectable
by agarose gel electrophoresis and ethidium bromide
staining. In parallel, a 2-ml aliquot from the RT mixture
was used for a single PCR of 40 cycles. The cycling
conditions were exactly as described in the experimental
section for the ﬁrst round of nested PCR. A 5-ml aliquot of
ampliﬁed DNA was then hybridized with the speciﬁc
probe and half of the mixture was applied to the strip.
A band in the test zone of the strip was observed for 10
K562 cells in the presence of 10
6 normal cells (Figure 3A).
The clinical evaluation of the proposed method was
carried out by using 22 samples from patients with the
b3-a2 transcript and 5 samples containing the b2-a2
transcript. Two patients with essential thrombocythemia
were also included as negative controls. The Ph
1 chromo-
some positive patients were undergoing treatment. All
blood samples were subjected to the preparation steps
described in the experimental section, for isolation of
leukocytes, puriﬁcation of mRNA, cDNA synthesis,
nested PCR and detection by the strip. Ampliﬁcation
products were also analyzed by agarose gel electropho-
resis. The results are presented in Figure 3B and C. It is
observed that the strip test compares well with the
electrophoresis results. Sample No. 7 was found negative
both by electrophoresis and the strip test. Figure 4 shows
typical results of the dipstick assay for the reference gene
actin.
Two major types of mRNA are formed as a result of the
Philadelphia translocation. Either BCR exon 3 or BCR
exon 2 is joined to ABL exon 2 to generate the b3-a2 or
the b2-a2 fusion transcript, respectively. Because the two
pairs of primers used in nested PCR bind to BCR exon 2
and ABL exon 2, ampliﬁcation product is produced
regardless of the type of the transcript. We ﬁrst detect
transcripts b3-a2 and b2-a2 by using probes b3-a2 and
b2-a2, respectively. However, because these probes share a
common sequence (speciﬁc to ABL exon 2) we observed
signiﬁcant cross-hybridization with the two transcripts. In
order to identify, unambiguously, the type of the
transcript involved, we designed a probe speciﬁc for
BCR exon 3 (probe b3). The PCR products of the samples
that were found positive with probes b3-a2 or b2-a2, were
subjected to another dipstick assay using probe b3.
Samples that contain the b3-a2 transcript give a positive
result with the b3 probe, whereas samples that contain the
b2-a2 transcript give no signal. Figure 4 shows typical
results of the dipstick assay (probe b3) for samples
containing b3-a2 or b2-a2 transcripts.
PML-RARa and AML1-ETO
The detection of the translocation PML-RARa was based
on the analysis of the cell line NB4, one patient positive
for the translocation and a patient negative for the
translocation. The results are shown in Figure 5. A faint
red band appears in the test zone of the strip at 0.4fmol of
ampliﬁed DNA (40 pM) and the intensity increases with
the amount of loaded DNA, up to 400fmol. The
corresponding electropherogram shows a faint zone at
6.4fmol of ampliﬁed DNA.
For the detection of the translocation AML1-ETO, we
were based on two patients (Figure 5). A red line is clearly
detectable at the 0.4fmol target DNA whose intensity
increases with the amount of target DNA, up to 100fmol.
The signal is lower at 400fmol DNA due to competi-
tion between reannealing of target strands and probe
hybridization, as described above for BCR-ABL. The
detectability by electrophoresis was 6.4fmol.
PAGE 7 OF 12 Nucleic Acids Research, 2007, Vol. 35, No. 4 e23CBFb-MYH11, PLZF-RARa, NPM-RARa and
NuMA-RARa
The RNA for the analysis of CBFb-MYH11 was received
from a patient who was positive for the translocation.
The lowest amount of ampliﬁed DNA that is detectable
by visual inspection of the strip is 1.6fmol (160 pM)
(Figure 6). The plasmids pSG5-PLZF-RARa, pSG5-
NPM-RARa and pSG5-NuMA-RARa were used for the
analysis of PLZF-RARa, NPM-RARa and NuMA-
RARa, respectively. Results pertaining to the detectability
of the strip assay are presented in Figure 6. In all three
translocations, the strip could detect easily 1.6fmol(160
pM) of ampliﬁed DNA.
Specificity ofthe dipstick hybridization assay
The speciﬁcity of the proposed method is based both on
the PCR step and the dipstick hybridization assay.
Because the primer binding sites ﬂank the junction
sequence, ampliﬁcation product is generated only if the
translocation is present. Furthermore, the dipstick test
allows conﬁrmation of the ampliﬁed sequence by hybridi-
zation. We performed a series of experiments in order to
study the speciﬁcity of the dipstick assay. Ampliﬁcation
products (50 fmol) from the seven translocations were
hybridized, on a one-to-one basis, with each of the probes
and the mixture was applied to the strip. It is observed (see
MN1A7B P 1
N1A7B P 1
1 1 41 62 2S 1S 2S 3S 4S 5
Actin
b3 probe
BCR-ABL transcript typing
Figure 4. Left panel: Typical results for actin by the dipstick assay and
agarose (2%) gel electrophoresis. The numbers correspond to patient
numbers of Figure 3. Right panel: Typing of the fusion transcripts
(b3-a2 and b2-a2) of the Philadelphia translocation. Following a
positive dipstick test with probes b3-a2 and b2-a2, the PCR product is
subjected to another dipstick assay using probe b3. Samples 1, 14, 16
and 22, which contain the b3-a2 transcript, give a positive result with
the b3 probe. However, no signal is obtained with samples S1-S5 that
contain the b2-a2 transcript.
200 bp 
N     C      A      B      1      2     3      4       5       6      7      8      9     10    11    12     13    14    15    16    17     18    19     20    21   22
BCR-ABL samples (b3-a2 transcript)
N S1    S2  S3  S4  S5 
M N  S1  S2  S3 M  N  S4  S5 
124 bp
BCR-ABL samples (b2-a2 transcript)
(B)
M N C 1 3 4 M A 6 7 9 M B 10 12 13 5 14 15 M 16 M 17 18 19 20 M 8 21 2 22 11
(C)
K562 cells (1-106 cells) (A)
N 0 1 10  102 103 104 105 106
N 0 1 10  102 103 104 105 106
Nested PCR
Single PCR
Figure 3. (A) Dry-reagent dipstick test for the detection of K562 cells in the presence of normal leukocytes. K562 cells were mixed with normal
leukocytes to cover a range of 0–10
6 K562 cells in a total number of 10
6 cells. Following total RNA isolation, reverse transcription and single or
nested PCR, the products were assayed by the dry-reagent dipstick hybridization. (B) Application of the dipstick test to the detection of the BCR-
ABL b3-a2 fusion transcripts in chronic myelogenous leukemia patients. Samples from two patients with essential thrombocythemia were also
included as negative controls (samples A and B). (C) Application of the dipstick test to the detection of the BCR-ABL b2-a2 fusion transcripts in
chronic myelogenous leukemia patients. The electropherograms (2% agarose gels and ethidium bromide staining) are also presented for direct
comparison. M¼DNA markers; C¼K562 cells; N¼negative (no RNA in the reverse transcription reaction mixture).
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sequence.
Reproducibility
The reproducibility of the strip assay was assessed by
assaying 6.4 and 50fmoltarget DNA (PCR products) ﬁve
times (Figure 8). The strips were then scanned (desktop
scanner ScanJet 4300C, Hewlett Packard) and the
intensity of the test zone was estimated densitometrically.
The coeﬃcient of variation (CV) (relative standard
deviation) of the intensity was 7.6 and 4.9%, respectively.
To determine the overall reproducibility of the test, three
samples containing 12.8 pg, 1.6 10
3 pg and 10
6 pg RNA
from Ph
1 cells were subjected, in quadruplicate, to reverse
transcription, nested PCR and strip assay (Figure 8). The
test zones of the strips were analyzed by scanning and
densitometry as above and the CV were found to be 29,
10.7 and 8.5%, respectively. Finally, we assessed
the reproducibility of the detection of 1 K562 cell in the
M    0    0.4   1.6    6.4   25   100   400 M     0     0.4   1.6    6.4    25   100   400
366bp
0     0.4     1.6   6.4     25  100   400
PML-RARa target (fmol)
N      P1     P2 NB4
M    N   P1  P2   NB4
0      0.4     1.6     6.4     25    100    400
260bp 
AML1-ETO target (fmol)
N        P3       P4
M      N      P3     P4
Figure 5. Dipstick test for the detection of PML-RARa (left panel) and AML1-ETO (right panel) transcripts. The target DNA was diluted in PCR
buﬀer (67 mM Tris-HCl, pH 8.8, 16.6 mM (NH4)2SO4 and 0.1 ml/l Tween-20). The results obtained by agarose (2%) gel electrophoresis and
ethidium bromide staining are also presented for direct comparison. N¼RT negative (water instead of RNA in the RT mixture); P1¼patient
negative for the PML-RARa translocation; P2¼patient positive for the PML-RARa translocation; P3 and P4¼patients positive for the AML1-ETO
translocation. NB4¼RNA from NB4 cell line, that carries the PML-RARa translocation.
0       0.4    1.6     6.4    25    100    400
M      0     0.4    1.6    6.4    25   100  400
271bp
CBFb-MYH11 target (fmol)
267bp
M       0    0.4     1.6    6.4    25   100   400
0      0.4    1.6     6.4      25     100    400
PLZF-RARa target (fmol)
0      0.4     1.6    6.4     25     100   400
315bp
M       0    0.4    1.6    6.4    25  100  400
NuMA-RARa target (fmol)
0      0.4     1.6     6.4    25    100    400
M      0    0.4   1.6   6.4  25  100  400
423bp 
NPM-RARa target (fmol)
Figure 6. Dipstick test for the detection of CBFb-MYH11, PLZF-RARa, NPM-RARa and NuMA-RARa fusions. The target DNA was diluted in
PCR buﬀer (67 mM Tris-HCl, pH 8.8, 16.6 mM (NH4)2SO4 and 0.1 ml/l Tween-20). The electropherograms (2% agarose gels and ethidium bromide
staining) are also presented for comparison.
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6 normal cells. The CV after scanning and
densitometry of the test zones of the strips was 22%
(n¼4).
Conclusions
In recent years, several clinical investigations have
constantly demonstrated the importance of molecular
tests in the management of acute and chronic leukemia
patients. PCR is by far the most sensitive method for
diagnosis, classiﬁcation of risk groups and assessment of
minimal residual disease during follow up. The detection
of the type of translocation by a qualitative PCR assay is
suﬃcient for the diagnosis and correct assignment of risk
group. The gold standard for screening of these transloca-
tions is cytogenetics and PCR combined with agarose gel
electrophoresis. For this reason, throughout this work, we
compare the proposed dipstick assay directly to agarose
gel electrophoresis. However, the evaluation of minimal
residual disease is more challenging. A negative PCR
result (absence of the fusion transcript in the sample)
usually predicts a favorable outcome. On the other hand,
if the screening test is positive (i.e. residual leukemic cells
are present), this is not necessarily associated with a
relapse. In this case, a quantitative PCR assay for the
determination of the concentration of fusion transcripts
over a period of time is a more reliable indicator of the
progression of the disease (26,27). The proposed dipstick
assay is not a quantitative test but rather a rapid and cost-
eﬀective visual screening test before a decision for
quantiﬁcation is made. Nevertheless, we have analyzed
ﬁve BCR-ABL samples by real-time PCR and the dipstick
assay. The strips were then scanned and the intensity of
the test zone was estimated densitometrically. The real-
time PCR (Light cycler) values were 3.2, 173, 224, 992 and
7400, using glucose-6-phosphate dehydrogenase (G6PD)
as a reference gene. The dipstick assay gave 11, 133, 459,
394, 560, respectively. These results conﬁrm that the
dipstick assay should be used only for screening purposes.
The nested PCR-dipstick method can detect 1 K562 cell
whereas the single PCR-dipstick assay detects 10 K562
cells (see Figure 3). It is well established in the literature
(28–30) that the sensitivity of real-time PCR is limited to
about 10 or 100 K562 cells amidst 10
6 normal cells.
Therefore, the sensitivity of the single PCR-dipstick test is
similar to that of real-time PCR. Furthermore, the
combination of nested PCR with the dipstick assay
(although more laborious) provides a 10-fold improve-
ment in sensitivity. This diﬀerence in sensitivity is
b3-a2 probe (BCR-ABL)
1       2       3      4       5      6      7
PML-RARa probe
1       2      3      4       5       6      7
AML1-ETO probe
1       2       3      4      5       6      7
CBFb-MYH11 probe
1       2       3      4      5      6       7
PLZF-RARa probe
1       2      3       4      5       6      7
NPM-RARa probe
1       2      3      4       5      6       7
NuMA-RARa probe
1       2      3      4      5       6      7
Figure 7. Study of the speciﬁcity of the dry-reagent dipstick hybridization assay. Ampliﬁcation products (50 fmol) from the seven translocations were
hybridized, on a one-to-one basis, with each of the probes and the mixture was applied to the strip. The numbers correspond to ampliﬁed DNA
sequences (PCR products) of the seven translocations, as follows: 1: BCR-ABL (b3-a2); 2: PML-RARa; 3: PLZF-RARa; 4: NPM-RARa; 5: NuMA-
RARa; 6: AML1-ETO; 7: CBFb-MYH11.
Reproducibility
12.8 pg 106 pg 1.6x103 pg
RNA
6.4 fmol 50 fmol
Amplified DNA
Figure 8. Study of the reproducibility of the dipstick test using
ampliﬁcation products from the BCR-ABL translocation (two PCR
pools) and total RNA from K562 cells.
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34) state that complete remission in CML should be
deﬁned as negativity by nested PCR for BCR-ABL due to
its superior sensitivity compared to real-time PCR. In
recent studies for monitoring minimal residual disease,
negative real-time PCR results need to be conﬁrmed by
nested PCR (31–34).
A comparison of the single round PCR-dipstick method
with the real-time PCR (two methods of similar sensitiv-
ity) in terms of cost and practicality reveals the following:
(a) The dipstick method can be performed simply by using
a classical PCR instrument that constitutes standard
equipment of every molecular diagnosis laboratory. On
the contrary, the investment cost for a real-time PCR
instrument is over 10 times higher than classical PCR. (b)
The cost of the probes used in real-time PCR (e.g.
Taqman and FRET probes) is at least 7 times higher than
the probes used in the proposed method. (c) The dry-
reagent dipstick format eliminates the solution prepara-
tion steps, it is very simple to perform and minimizes the
training of qualiﬁed personnel.
We estimated that the cost of the dipstick assay is less
than 2 Euros. The dipstick assay oﬀers about 10 times
higher detectability than agarose gel electrophoresis and
ethidium bromide staining and, contrary to electropho-
resis, allows conﬁrmation of the sequence of the PCR
product by hybridization within a few minutes without the
need of instrumentation. The dipstick assay requires PCR
products that are biotinylated at the 50 end (during PCR)
along with a poly(dA)-tailed probe speciﬁc for the
junction sequence. The dry-reagent disposable strip
format greatly simpliﬁes the assay because it eliminates
the multiple incubation and washing steps performed in
current hybridization assays.
ACKNOWLEDGMENTS
This work was supported by a University-Industry
collaboration grant (EPAN) funded by the General
Secreteriat of Research and Technology (GSRT) of
Greece and by Medicon Hellas S.A. (Gerakas, Greece
15344). We are grateful to Dr V. Drakopoulos (FORTH/
ICE-HT) for carrying out the SEM analysis of the strip.
We also express our gratitude to Dr J. Licht for providing
the plasmids pSG5-PLZF-RARa, pSG5-NPM-RARa and
pSG5-NuMA-RARa and Dr P. Ziros (University of
Patras, Medical School) for growing the plasmids. We
thank Dr A. Mougiou (University of Patras, Medical
School) for making available to us the real-time PCR
results along with the corresponding total RNA, and Dr
D. Mavrogianni (Laikon Hospital, University of Athens
Medical School) for providing samples containing the b2-
a2 transcript.
REFERENCES
1. Bench,A.J., Erber,W.N. and Scott,M.A. (2005) Molecular genetic
analysis of haematological malignancies: I. Acute leukemias and
myeloproliferative disorders. Clin. Lab. Haem., 27, 148–171.
2. Crisan,D. (2000) Molecular mechanisms in myelodysplastic
syndromes and implications for evolution to acute leukemias. Clin.
Lab. Med., 20, 49–69.
3. Pandolﬁ,P.P. (2001) Oncogenes and tumor suppressors in the
molecular pathogenesis of acute promyelocytic leukemia. Hum.
Mol. Genet., 10, 769–775.
4. Liu Yin,J.A. (2002) Minimal residual disease in acute myeloid
leukemia. Best Pract. Res. Clin. Haematol., 15, 119–135.
5. Liu Yin,J.A. (1999) Detection of minimal residual disease in acute
myeloid leukemia: methodologies, clinical and biological signiﬁ-
cance. Br. J. Haematol., 106, 578–590.
6. Burmeister,T. and Thiel,E. (2001) Molecular genetics in acute and
chronic leukemias. J. Cancer Res. Clin. Oncol., 127, 80–90.
7. Falini,B. and Mason,D.Y. (2002) Proteins encoded by genes
involved in chromosomal alterations in lymphoma and leukemia:
clinical value of their detection by immunocytochemistry. Blood, 99,
409–426.
8. Bortolin,S. and Christopoulos,T.K. (1994) Time-resolved immuno-
ﬂuorometric determination of speciﬁc mRNA sequences ampliﬁed
by the polymerase chain reaction. Anal. Chem., 66, 4302–4307.
9. Bortolin,S. and Christopoulos,T.K. (1995) Detection of BCR-ABL
transcripts from the philadelphia translocation by hybridization in
microtiter wells and time-resolved immunoﬂuorometry. Clin. Chem.,
41, 693–699.
10. Zhang,Q.Y., Garner,K. and Viswanatha,D.S. (2002) Rapid detec-
tion of leukemia-associated translocation fusion genes using a novel
combined RT-PCR and ﬂow-cytometric method. Leukemia, 16,
144–149.
11. Chen,I.M., Chakerian,A., Combs,D., Garner,K. and
Viswanatha,D.S. (2004) Post-PCR multiplex ﬂuorescent ligation
detection assay and ﬂow cytometry for rapid detection of gene-speciﬁc
translocations in leukemia. Am. J. Clin. Pathol., 122, 783–793.
12. Nashed,A.L., Rao,K.W. and Gulley,M.L. (2003) Clinical applica-
tions of BCR-ABL molecular testing in acute leukemia. J. Mol.
Diagn., 5, 63–72.
13. Zhang,T., Xiong,H., Kan,L.-X., Zhang,C.-K., Jiao,X.-F., Fu,G.,
Zhang,Q.-H., Lu,L., Tong,J.-H., Gu,B.-W. et al. (1999) Genomic
sequence, structural organization, molecular evolution, and aberrant
rearrangement of promyelocytic leukemia zinc ﬁnger gene. Proc.
Natl. Acad. Sci. U.S.A., 96, 11422–11427.
14. Yin,J.A. and Frost,L. (2003) Monitoring AML1-ETO and
CBFbeta-MYH11 transcripts in acute myeloid leukemia. Curr.
Oncol. Rep., 5, 399–404.
15. Shigesada,K., van de Sluis,B. and Liu,P.P. (2004) Mechanism of
leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-
MYH11. Oncogene, 23, 4297–4307.
16. Glynou,K., Ioannou,P.C., Christopoulos,T.K. and Syriopoulou,V.
(2003) Oligonucleotide-functionalized gold nanoparticles as probes
in a dry-reagent strip biosensor for DNA analysis by hybridization.
Anal. Chem., 75, 4155–4160.
17. Li,J.Y., English,M.A., Ball,H.J., Yeyati,P.L., Waxman,S. and
Licht,J.D. (1997) Sequence-speciﬁc DNA binding and transcrip-
tional regulation by the promyelocytic leukemia zinc ﬁnger protein.
J. Biol. Chem., 272, 22447–22455.
18. Licht,J.D., Shaknovich,R., English,M.A., Melnick,A., Li,J.Y.,
Reddy,J.C., Dong,S., Chen,S.J., Zelent,A. and Waxman,S. (1996)
Reduced and altered DNA-binding and transcriptional properties of
the PLZF-retinoic acid receptor-alpha chimera generated in
t(11;17)-associated acute promyelocytic leukemia. Oncogene 12,
323–336.
19. Grimwade,D., Biondi,A., Mozziconacci,M.J., Hagemeijer,A.,
Berger,R., Neat,M., Howe,K., Dastugue,N., Jansen,J., Radford-
Weiss,I. et al. (2000) Characterization of acute promyelocytic
leukemia cases lacking the classic t(15;17): results of the European
Working Party. Blood, 96, 1297–1307.
20. Jansen,J.H., de Ridder,M.C., Geertsma,W.M.C., Erpelinck,C.A., van
Lom,K., Smit,E.M.E., Slater,R., vd Reijden,B.A., de Greef,G.E.,
Sonneveld,P. et al. (1999) Complete remission of t(11;17) Positive
acute promyelocytic leukemia induced by all-trans retinoic acid and
granulocyte colony-stimulating factor. Blood, 94, 39–45.
21. Wells,R.A., Catzavelos,C. and Kamel-Reid,S. (1997) Fusion of
retinoic acid receptor  to NuMA, the nuclear mitotic apparatus
protein, by a variant translocation in acute promyelocytic leukemia.
Nature Genet., 17, 109–113.
PAGE 11 OF 12 Nucleic Acids Research, 2007, Vol. 35, No. 4 e2322. Van Dongen,J.J.M., Macintyre,E.A., Gabert,J.A., Delabesse,E.,
Rossi,V., Saglio,G., Gottardi,E., Rambaldi,A., Dotti,G.,
Griesinger,F. et al. (1999) Standarized RT-PCR analysis of
fusion gene transcripts from chromosome aberrations in acute
leukemia for detection of minimal residual disease. Leukemia, 13,
1901–1928.
23. Galvan,B. and Christopoulos,T.K. (1997) Quantitative reverse
transcriptase-polymerase chain reaction for prostate-speciﬁc antigen
mRNA. Clin. Biochem., 30, 391–397.
24. Weller,M.G. (2000) Immunochromatographic techniques-a critical
review. Fresenius J. Anal. Chem., 366, 635–645.
25. Hayat,M.A. (1989) Colloidal gold: Principles, methods and applica-
tions. Academic press, CA. Academic press, CA.
26. Schnittger,S., Weisser,M., Schoch,C., Hiddemann,W., Haferlach,T.
and Kern,W. (2003) New score predicting for prognosis in
PML-RARA
þ, AML1-ETO
þ, or CBFB-MYH11
þ acute myeloid
leukemia based on quantiﬁcation of fusion transcripts. Blood, 102,
2746–2755.
27. Bortolin,S. and Christopoulos,T.K. (1996) Quantitative RT-PCR
combined with time-resolved ﬂuorometry for determination of
BCR-ABL mRNA. Clin.Chem., 42, 1924–1929.
28. Schu ¨ ler,F. and Do ¨ lken,G. (2006) Detection and monitoring of
minimal residual disease by quantitative real-time PCR. Clin. Chim.
Acta, 363, 147–156.
29. Press,R.D., Love,Z., Tronnes,A.A., Yang,R., Tran,T.,
Mongoue-Tchokote,S., Mori,M., Mauro,M.J., Deininger,M.W. and
Druker,B.J. (2006) BCR-ABL mRNA levels at and after the time of a
complete cytogenetic response (CCR) predict the duration of CCR in
imatinib mesylate-treated patients with CML. Blood, 107, 4250–4256.
30. Neumann,F., Herold,C., Hildebrandt,B., Kobbe,G., Aivado,M.,
Rong,A., Free,M., Ro ¨ ssig,R., Fenk,R., Schneider,P. et al. (2003)
Quantitative real-time reverse-transcription polymerase
chain reaction for diagnosis of BCR-ABL positive
leukemias and molecular monitoring following allogeneic stem cell
transplantation. Eur. J. Haematol., 70, 1–10.
31. Elmaagacli,A.H., Beelen,D.W., Opalka,B., Seeber,S. and
Schaefer,U.W. (2000) The amount of BCR-ABL fusion transcripts
detected by the real-time quantitative polymerase chain reaction
method in patients with Philadelphia chromosome positive chronic
myeloid leukemia correlates with the disease stage. Ann. Hematol.,
79, 424–431.
32. Deininger,M.W. (2005) Management of early stage disease.
Hematology, 1, 174–182.
33. Thomas,D.A., Faderl,S., Cortes,J., O’Brien,S., Giles,F.J.,
Kornblau,S.M., Garcia-Manero,G., Keating,M.J., Andreeﬀ,M. and
Jeha,S. (2004) Treatment of Philadelphia chromosome-positive
acute lymphocytic leukemia with hyper-CVAD and imatinib
mesylate. Blood, 103, 4396–4407.
34. Guo,J.Q., Lin,H., Kantarjian,H., Talpaz,M., Champlin,R.,
Andreeﬀ,M., Glassman,A. and Arlinhaus,R.B. (2002) Comparison
of competitive-nested PCR and real-time PCR in detecting BCR-
ABL fusion transcripts in chronic myeloid leukemia patients.
Leukemia, 16, 2447–2453.
e23 Nucleic Acids Research, 2007, Vol. 35, No. 4 PAGE 12 OF 12